Time to Educate Your Dermatologist about Diagnosing Skin Cancer
Suspicious pigmented lesions or ‘moles’ are a common presenting problem in a GPs Medical Practice. Most lesions are benign however a small minority are malignant melanomas. When a GP recognizes a suspicious mole, caution is taken and patients are referred to a dermatologist.
Over the last twenty-five years, the incidence of melanoma has increased more than for any other major cancer in the US at an alarming rate. Worldwide, the incidence of melanoma is increasing faster than any other cancer with an approximate doubling of rates every 10-20 years in countries with white populations.
Although the incidence of melanoma increases with age, a third of all cases occur in people aged less than fifty years and it is the second most common cancer in the 20-39 age-group. The increasing incidence has been attributed to increases in UV exposure, both natural and artificial, and to associated advances in early diagnosis. Other risk factors include genetic predisposition, fair complexion, sunburn-susceptible skin types, and family history
In 2009, up to nineteen out of every twenty lesions referred to a skin specialist (dermatologist) by a GP under the two-week cancer standard were benign. Alternative approaches are therefore required to increase the precision of assessment of pigmented skin lesions in primary care and therefore reduce the number of unnecessary referrals of benign lesions. This will be beneficial not only in secondary care, but also to reduce unnecessary patient anxiety.
The MoleMate system is a small hand-held scanner linked to a computer program, which has been designed for use in general practices to help the doctor or nurse assess a mole. The system uses SIAscopy (a non-invasive scanning technique) to produce images of the mole. The images are then assessed and a decision made as to whether or not the mole should be referred and looked at in more detail by a dermatologist.
The FDA approved SIMSYS-MoleMate Skin Imaging System, a non-invasive skin cancer screening procedure, is a significant advance in the early detection of potentially life threatening moles and lesions.
Physicians have found the SIMSYS-MoleMate Siascope hand-held device easy to learn and use, and that it rapidly provides accurate images of the pigment, blood, and collagen below the mole or lesion.
Now, for the first time, physicians can more accurately evaluate suspicious moles and lesions in a non-invasive, pain-free way. Experts also believe it may reduce the need for time consuming and expensive biopsies. For more information about SIMSYS-MoleMate,
MedX Health Corp.